Medical Xpress December 15, 2025
Respiratory viruses that have diverse strains and mutate rapidly, such as influenza and COVID-19, are difficult to block perfectly with vaccines alone. To solve this problem, KAIST’s research team has successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments—namely, being weak against heat and disappearing quickly from the nasal mucosa.
A joint research team—consisting of Professor Ho Min Kim and Professor Hyun Jung Chung from the Department of Biological Sciences, and Professor Ji Eun Oh from the Graduate School of Medical Science and Engineering—used AI to stably redesign the interferon-lambda protein and combined it with a delivery technology that ensures effective diffusion and long-term retention in the nasal mucosa, thereby implementing a...
Today's Sponsors
Today's Sponsor